NCT03755713View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

October 11, 2021

Study Completion Date

October 11, 2021

Conditions

Peanut Allergy

Interventions

DRUG

ASP0892

Intradermal

DRUG

Placebo

Intradermal; normal saline solution

Trial Locations (7)

10029

Icahn School of Medicine at Mount Sinai, New York

45241

Cincinnati Children's Hospital Medical Center, Cincinnati

60637

The University of Chicago Medicine, Chicago

72205

Arkansas Children's Hospital Research Institute, Little Rock

94090

Sean N Parker Center for Allergy & Asthma Research, LPCH El Camino Hospital, Mountain View

98115

Asthma, Inc., Seattle

02114

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT03755713 - A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine | Biotech Hunter | Biotech Hunter